Inmaculada B. Aban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Inmaculada B. Aban has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Anthony R. Miller
17 shared publications- Elaine R. Mardis
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, USA
17 shared publications - G. Yancey Gillespie
10Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama
17 shared publications - James M. Markert
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
17 shared publications Jennifer Clements
17 shared publications- Jianmei Wu Leavenworth
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA
17 shared publications
Latest Publications
- 10 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study
Background: Ganciclovir remains the primary therapeutic for cytomegalovirus (CMV) infections in early infancy, but its pharmacokinetics and dosing in very preterm infants with end-organ CMV disease have not been fully evaluated. Methods: Premature infants with confirmed CMV infection and receiving ganciclovir as standard of care were enrolled into a pharmacokinetic (PK) sampling study. All infants were 500 g at enrollment. Plasma for ganciclovir quantitation was collected at steady state at 0, 1, 2–3, 5–7, and 10–12 hours after the dose. Specimens were shipped and analyzed, and PK parameters were calculated in real time. Noncompartmental and modeling approaches were used for analysis. Results: Eighteen infants were enrolled; their mean gestational age at delivery was 26.7 weeks, and their mean age and weight at enrollment were 42 days and 1519.0 g, respectively. PK assessments were completed in 17. The geometric mean dose and resulting 12-hour area under the curve were 5.19 mg/kg and 52.7 mg · h/L, respectively. A total of 85 ganciclovir concentration-time data points were available for modeling. A 1-compartment power covariate model with weight and serum creatinine on clearance and weight on distribution volume was used. Noncompartmental and modeled PK parameters were similar. Conclusions: These are the first intravenous ganciclovir population PK data with covariate assessments in premature infants being treated for CMV disease. Results suggest an intravenous dose of 5 mg/kg every 12 hours may be an appropriate starting regimen in of premature infants with congenital CMV. Additional data are needed in this and other populations to better define optimal ganciclovir exposure targets.
- 10 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study
Background: Ganciclovir remains the primary therapeutic for cytomegalovirus (CMV) infections in early infancy, but its pharmacokinetics and dosing in very preterm infants with end-organ CMV disease have not been fully evaluated. Methods: Premature infants with confirmed CMV infection and receiving ganciclovir as standard of care were enrolled into a pharmacokinetic (PK) sampling study. All infants were 500 g at enrollment. Plasma for ganciclovir quantitation was collected at steady state at 0, 1, 2–3, 5–7, and 10–12 hours after the dose. Specimens were shipped and analyzed, and PK parameters were calculated in real time. Noncompartmental and modeling approaches were used for analysis. Results: Eighteen infants were enrolled; their mean gestational age at delivery was 26.7 weeks, and their mean age and weight at enrollment were 42 days and 1519.0 g, respectively. PK assessments were completed in 17. The geometric mean dose and resulting 12-hour area under the curve were 5.19 mg/kg and 52.7 mg · h/L, respectively. A total of 85 ganciclovir concentration-time data points were available for modeling. A 1-compartment power covariate model with weight and serum creatinine on clearance and weight on distribution volume was used. Noncompartmental and modeled PK parameters were similar. Conclusions: These are the first intravenous ganciclovir population PK data with covariate assessments in premature infants being treated for CMV disease. Results suggest an intravenous dose of 5 mg/kg every 12 hours may be an appropriate starting regimen in of premature infants with congenital CMV. Additional data are needed in this and other populations to better define optimal ganciclovir exposure targets.
- 1 September 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (9) , 526-550
Multidimensional biocircuitry of exercise adaptation: integrating in vivo and ex vivo phenomics with miRNA mapping
We examined in vivo and ex vivo adaptations to traditional moderate-intensity endurance and resistance training (TRAD) versus high-intensity tactical training (HITT; explosive whole-body interval training and high-intensity resistance training). TRAD and HITT improved physiological performance and body composition, and induced ex vivo muscle adaptations, with remarkable interindividual response heterogeneity (IRH) in improvements. We leveraged multidimensional modeling to identify interindividual response heterogeneity biocircuitry that integrates deep phenotyping and miR transcriptomics (serum exosomes and skeletal muscle).
- 1 September 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (9) , 526-550
Multidimensional biocircuitry of exercise adaptation: integrating in vivo and ex vivo phenomics with miRNA mapping
We examined in vivo and ex vivo adaptations to traditional moderate-intensity endurance and resistance training (TRAD) versus high-intensity tactical training (HITT; explosive whole-body interval training and high-intensity resistance training). TRAD and HITT improved physiological performance and body composition, and induced ex vivo muscle adaptations, with remarkable interindividual response heterogeneity (IRH) in improvements. We leveraged multidimensional modeling to identify interindividual response heterogeneity biocircuitry that integrates deep phenotyping and miR transcriptomics (serum exosomes and skeletal muscle).
- Open Access
- 18 July 2025
- Published by Springer Nature in Child's Nervous System
- Vol. 41 (1) , 237
A global survey of neurosurgeons’ awareness of neural tube defect prevalence, prevention strategies, and their clinical time allocation to spina bifida care
Purpose: Assess the global neurosurgeon workforce’s awareness of neural tube defect (NTD) prevalence, prevention strategies, and clinical time spent on spina bifida (SB) care. Methods: An online survey was administered to neurosurgeons worldwide between 2021-2022. Categorical responses were analyzed using descriptive analysis. Adjusted and unadjusted logistic regression analyses were conducted to examine the association between the clinical time spent on SB care and NTD prevalence awareness, controlling for sex, income region, pediatric training, and practice years, estimating odds ratios (ORs) and 95% confidence intervals (CIs). Results: Overall, 234 neurosurgeons (71% participation rate) responded from 64 countries. Respondents included 166 (77%) non-US residents practicing in non-high-income-country (non-HIC) (49%). Most were male (78%), 31-60 years old (80%), and urban-based (76%). Approximately quarter were unaware of the NTD prevalence at the national (28%) or global (24%) level, or the effectiveness of folic acid fortification (FAF) (27%). About 17% reported NTD rates ≥ 20/10,000 live births in their country. Neurosurgeons most often cited supplementation pills (46%) and flour FAF (36%) as the most common strategies to prevent NTD pregnancies. They were more likely to prefer strategies based on flour FAF (48%) and salt FAF (35%). There was a significant positive association between practicing in non-HIC and spending ≥ 20% of clinical time caring for SB (aOR = 6.42, 95% CI = 2.66-15.46, p < 0.001). Conclusions: This study highlights the need to improve awareness of NTD prevalence and preventive strategies among the neurosurgical community. There is a significant disparity in time spent on SB care between HIC and non-HIC countries. Neurosurgeons can serve as key advocates for global and local SB prevention efforts, with particular emphasis on FAF.
- 18 July 2025
- Published by Springer Nature in Child's Nervous System
- Vol. 41 (1) , 237
Open AccessA global survey of neurosurgeons’ awareness of neural tube defect prevalence, prevention strategies, and their clinical time allocation to spina bifida care
Purpose: Assess the global neurosurgeon workforce’s awareness of neural tube defect (NTD) prevalence, prevention strategies, and clinical time spent on spina bifida (SB) care. Methods: An online survey was administered to neurosurgeons worldwide between 2021-2022. Categorical responses were analyzed using descriptive analysis. Adjusted and unadjusted logistic regression analyses were conducted to examine the association between the clinical time spent on SB care and NTD prevalence awareness, controlling for sex, income region, pediatric training, and practice years, estimating odds ratios (ORs) and 95% confidence intervals (CIs). Results: Overall, 234 neurosurgeons (71% participation rate) responded from 64 countries. Respondents included 166 (77%) non-US residents practicing in non-high-income-country (non-HIC) (49%). Most were male (78%), 31-60 years old (80%), and urban-based (76%). Approximately quarter were unaware of the NTD prevalence at the national (28%) or global (24%) level, or the effectiveness of folic acid fortification (FAF) (27%). About 17% reported NTD rates ≥ 20/10,000 live births in their country. Neurosurgeons most often cited supplementation pills (46%) and flour FAF (36%) as the most common strategies to prevent NTD pregnancies. They were more likely to prefer strategies based on flour FAF (48%) and salt FAF (35%). There was a significant positive association between practicing in non-HIC and spending ≥ 20% of clinical time caring for SB (aOR = 6.42, 95% CI = 2.66-15.46, p < 0.001). Conclusions: This study highlights the need to improve awareness of NTD prevalence and preventive strategies among the neurosurgical community. There is a significant disparity in time spent on SB care between HIC and non-HIC countries. Neurosurgeons can serve as key advocates for global and local SB prevention efforts, with particular emphasis on FAF.
- Open Access
Multidimensional biocircuitry of exercise adaptation: integrating in vivo and ex vivo phenomics with miRNA mapping
In a randomized, dose-response trial, we used molecular and phenomic profiling to compare responses to traditional (TRAD) moderate intensity endurance and resistance training vs. high-intensity tactical training (HITT) that encompassed explosive whole-body interval training and high-intensity resistance training. Ninety-four participants (18-27 years) completed 12 weeks of TRAD or HITT followed by 4 weeks of detraining. Although similar performance and body composition improvements were observed in response to HITT and TRAD, some dose-dependent differences were observed for: (i) ex vivo muscle tissue changes in myofiber size, capillarization, satellite cell frequency, and mitochondrial function; and (ii) differential gene expression (DGE) of muscle and serum exosomal miRNAs (miRs). However, these dose-dependent ex vivo muscle adaptations were overshadowed by wide-ranging inter-individual response heterogeneity (IRH). We therefore explored IRH by first establishing minimum clinically important difference (MCID) scores to classify each participant based on MCIDs for functional muscle quality (fMQ) and cardiorespiratory fitness (CRF), and then modeling all data based on MCID classification. Using higher-order singular value decomposition (HOSVD), we established multidimensional biocircuitry linked to IRH that identified the most influential features across lifestyle, body composition, performance, ex vivo muscle tissue, and miRNA mapping domains. Via cross-comparison of MCID-linked miRs identified via DGE and HOSVD, nine miRs emerged as robust features of training adaptability, providing new insights into the integrated biocircuitry driving IRH. NEW & NOTEWORTHY: We examined in vivo and ex vivo adaptations to TRAD (traditional moderate-intensity endurance and resistance training) vs. HITT (high-intensity tactical training; explosive whole-body interval training and high-intensity resistance training). TRAD and HITT improved physiological performance and body composition, and induced ex vivo muscle adaptations, with remarkable inter-individual response heterogeneity (IRH) in improvements. We leveraged multidimensional modeling to identify IRH biocircuitry that integrates deep phenotyping and miR transcriptomics (serum exosomes, skeletal muscle).
Open AccessMultidimensional biocircuitry of exercise adaptation: integrating in vivo and ex vivo phenomics with miRNA mapping
In a randomized, dose-response trial, we used molecular and phenomic profiling to compare responses to traditional (TRAD) moderate intensity endurance and resistance training vs. high-intensity tactical training (HITT) that encompassed explosive whole-body interval training and high-intensity resistance training. Ninety-four participants (18-27 years) completed 12 weeks of TRAD or HITT followed by 4 weeks of detraining. Although similar performance and body composition improvements were observed in response to HITT and TRAD, some dose-dependent differences were observed for: (i) ex vivo muscle tissue changes in myofiber size, capillarization, satellite cell frequency, and mitochondrial function; and (ii) differential gene expression (DGE) of muscle and serum exosomal miRNAs (miRs). However, these dose-dependent ex vivo muscle adaptations were overshadowed by wide-ranging inter-individual response heterogeneity (IRH). We therefore explored IRH by first establishing minimum clinically important difference (MCID) scores to classify each participant based on MCIDs for functional muscle quality (fMQ) and cardiorespiratory fitness (CRF), and then modeling all data based on MCID classification. Using higher-order singular value decomposition (HOSVD), we established multidimensional biocircuitry linked to IRH that identified the most influential features across lifestyle, body composition, performance, ex vivo muscle tissue, and miRNA mapping domains. Via cross-comparison of MCID-linked miRs identified via DGE and HOSVD, nine miRs emerged as robust features of training adaptability, providing new insights into the integrated biocircuitry driving IRH. NEW & NOTEWORTHY: We examined in vivo and ex vivo adaptations to TRAD (traditional moderate-intensity endurance and resistance training) vs. HITT (high-intensity tactical training; explosive whole-body interval training and high-intensity resistance training). TRAD and HITT improved physiological performance and body composition, and induced ex vivo muscle adaptations, with remarkable inter-individual response heterogeneity (IRH) in improvements. We leveraged multidimensional modeling to identify IRH biocircuitry that integrates deep phenotyping and miR transcriptomics (serum exosomes, skeletal muscle).
- Open Access
- 1 August 2024
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 17
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
Background: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucoplan data past 12 weeks are not available. Objectives: Predict the treatment effect of zilucoplan versus control (placebo or standard of care) in patients with gMG up to 24 weeks. Design: A model-informed analysis (MIA) within a Bayesian framework. Methods: Part 1 of the MIA comprised a control meta-regression using aggregate data on control response over time from randomised studies and a national myasthenia gravis (MG) registry. In Part 2, a combined Bayesian analysis of individual patient-level data from the phase II (NCT03315130), RAISE (NCT04115293) and RAISE-XT (NCT04225871) studies of zilucoplan was conducted using posterior distributions from Part 1 as informative priors. Population mean treatment effect in the change from baseline (CFB) at week 24 in MG-Activities of Daily Living (MG-ADL) and quantitative MG (QMG) scores for zilucoplan versus control were assessed. Results: At week 24, the predicted mean CFB in MG-ADL score was −4.55 (95% credible interval: −6.04, −3.13) with zilucoplan versus −2.00 (−3.35, −0.64) with control (difference: −2.55 [−3.76, −1.40]). The probability of a favourable treatment effect as measured by MG-ADL score at week 24 with zilucoplan versus control was >99.9%. There was an 82.8% probability that the difference in the predicted mean CFB in MG-ADL score at week 24 was greater than the clinically meaningful threshold (⩾2.0-point improvement). Comparable results were observed with QMG. Conclusion: This MIA demonstrates the maintenance of efficacy with zilucoplan versus control up to 24 weeks. Through combining real-world evidence with data from randomised studies, this novel method to estimate long-term treatment efficacy facilitated reduced exposure to placebo in the phase III RAISE study. This methodology could be used to reduce the length of future placebo-controlled studies.
- 1 August 2024
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 17
Open AccessMaintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
Background: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucoplan data past 12 weeks are not available. Objectives: Predict the treatment effect of zilucoplan versus control (placebo or standard of care) in patients with gMG up to 24 weeks. Design: A model-informed analysis (MIA) within a Bayesian framework. Methods: Part 1 of the MIA comprised a control meta-regression using aggregate data on control response over time from randomised studies and a national myasthenia gravis (MG) registry. In Part 2, a combined Bayesian analysis of individual patient-level data from the phase II (NCT03315130), RAISE (NCT04115293) and RAISE-XT (NCT04225871) studies of zilucoplan was conducted using posterior distributions from Part 1 as informative priors. Population mean treatment effect in the change from baseline (CFB) at week 24 in MG-Activities of Daily Living (MG-ADL) and quantitative MG (QMG) scores for zilucoplan versus control were assessed. Results: At week 24, the predicted mean CFB in MG-ADL score was −4.55 (95% credible interval: −6.04, −3.13) with zilucoplan versus −2.00 (−3.35, −0.64) with control (difference: −2.55 [−3.76, −1.40]). The probability of a favourable treatment effect as measured by MG-ADL score at week 24 with zilucoplan versus control was >99.9%. There was an 82.8% probability that the difference in the predicted mean CFB in MG-ADL score at week 24 was greater than the clinically meaningful threshold (⩾2.0-point improvement). Comparable results were observed with QMG. Conclusion: This MIA demonstrates the maintenance of efficacy with zilucoplan versus control up to 24 weeks. Through combining real-world evidence with data from randomised studies, this novel method to estimate long-term treatment efficacy facilitated reduced exposure to placebo in the phase III RAISE study. This methodology could be used to reduce the length of future placebo-controlled studies.
- Open Access
- 15 May 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 39, 101306
Likelihood based inferences for trials incorporating participant’s treatment choice
- 15 May 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 39, 101306
Open AccessLikelihood based inferences for trials incorporating participant’s treatment choice
- 14 September 2023
- Published by Taylor & Francis in Journal of Applied Statistics
- Vol. 51 (11) , 2039-2061
The spike-and-slab lasso and scalable algorithm to accommodate multinomial outcomes in variable selection problems
Spike-and-slab prior distributions are used to impose variable selection in Bayesian regression-style problems with many possible predictors. These priors are a mixture of two zero-centered distributions with differing variances, resulting in different shrinkage levels on parameter estimates based on whether they are relevant to the outcome. The spike-and-slab lasso assigns mixtures of double exponential distributions as priors for the parameters. This framework was initially developed for linear models, later developed for generalized linear models, and shown to perform well in scenarios requiring sparse solutions. Standard formulations of generalized linear models cannot immediately accommodate categorical outcomes with > 2 categories, i.e. multinomial outcomes, and require modifications to model specification and parameter estimation. Such modifications are relatively straightforward in a Classical setting but require additional theoretical and computational considerations in Bayesian settings, which can depend on the choice of prior distributions for the parameters of interest. While previous developments of the spike-and-slab lasso focused on continuous, count, and/or binary outcomes, we generalize the spike-and-slab lasso to accommodate multinomial outcomes, developing both the theoretical basis for the model and an expectation-maximization algorithm to fit the model. To our knowledge, this is the first generalization of the spike-and-slab lasso to allow for multinomial outcomes.
- 14 September 2023
- Published by Taylor & Francis in Journal of Applied Statistics
- Vol. 51 (11) , 2039-2061
The spike-and-slab lasso and scalable algorithm to accommodate multinomial outcomes in variable selection problems
Spike-and-slab prior distributions are used to impose variable selection in Bayesian regression-style problems with many possible predictors. These priors are a mixture of two zero-centered distributions with differing variances, resulting in different shrinkage levels on parameter estimates based on whether they are relevant to the outcome. The spike-and-slab lasso assigns mixtures of double exponential distributions as priors for the parameters. This framework was initially developed for linear models, later developed for generalized linear models, and shown to perform well in scenarios requiring sparse solutions. Standard formulations of generalized linear models cannot immediately accommodate categorical outcomes with > 2 categories, i.e. multinomial outcomes, and require modifications to model specification and parameter estimation. Such modifications are relatively straightforward in a Classical setting but require additional theoretical and computational considerations in Bayesian settings, which can depend on the choice of prior distributions for the parameters of interest. While previous developments of the spike-and-slab lasso focused on continuous, count, and/or binary outcomes, we generalize the spike-and-slab lasso to accommodate multinomial outcomes, developing both the theoretical basis for the model and an expectation-maximization algorithm to fit the model. To our knowledge, this is the first generalization of the spike-and-slab lasso to allow for multinomial outcomes.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Data from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Data from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study